Variations in multiple sclerosis practice within Europe - Is it time for a new treatment guideline?
Autor(a) principal: | |
---|---|
Data de Publicação: | 2016 |
Outros Autores: | , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | http://hdl.handle.net/10400.4/2276 |
Resumo: | In the past 5 years, the combination of developments in diagnostic strategy and approval of new disease-modifying therapies has provided an opportunity to achieve dramatic improvements in patient outcomes in multiple sclerosis (MS). However, across Europe there are several factors that may prevent patients from receiving the best therapy at the appropriate time, and there is variation among countries in terms of which of these factors are most relevant. Here, we review current MS clinical practices in a number of countries in the European Union to identify differences regarding initiation of treatment in patients with clinically isolated syndrome or relapsing-remitting MS, and differences in the timing of treatment switch or escalation. While recognizing that policy is not static in any country, we believe that patients' interests would be better served if a European treatment guideline was developed. Such a guideline could both inform and be informed by national policies, facilitating the dissemination of best clinical practice internationally. |
id |
RCAP_5f482f96bf339786ec8acae71e63581b |
---|---|
oai_identifier_str |
oai:rihuc.huc.min-saude.pt:10400.4/2276 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
Variations in multiple sclerosis practice within Europe - Is it time for a new treatment guideline?EuropaEsclerose MúltiplaDisparidades em Assistência à SaúdePadrões de Prática MédicaIn the past 5 years, the combination of developments in diagnostic strategy and approval of new disease-modifying therapies has provided an opportunity to achieve dramatic improvements in patient outcomes in multiple sclerosis (MS). However, across Europe there are several factors that may prevent patients from receiving the best therapy at the appropriate time, and there is variation among countries in terms of which of these factors are most relevant. Here, we review current MS clinical practices in a number of countries in the European Union to identify differences regarding initiation of treatment in patients with clinically isolated syndrome or relapsing-remitting MS, and differences in the timing of treatment switch or escalation. While recognizing that policy is not static in any country, we believe that patients' interests would be better served if a European treatment guideline was developed. Such a guideline could both inform and be informed by national policies, facilitating the dissemination of best clinical practice internationally.RIHUCMarziniak, MGhorab, KKozubski, WPfleger, CSousa, LVernon, KZaffaroni, MMeuth, SG2020-03-21T19:24:05Z2016-072016-07-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10400.4/2276engMult Scler Relat Disord. 2016 Jul;8:35-44.10.1016/j.msard.2016.04.004info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-07-11T14:23:40Zoai:rihuc.huc.min-saude.pt:10400.4/2276Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T18:04:44.735821Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
Variations in multiple sclerosis practice within Europe - Is it time for a new treatment guideline? |
title |
Variations in multiple sclerosis practice within Europe - Is it time for a new treatment guideline? |
spellingShingle |
Variations in multiple sclerosis practice within Europe - Is it time for a new treatment guideline? Marziniak, M Europa Esclerose Múltipla Disparidades em Assistência à Saúde Padrões de Prática Médica |
title_short |
Variations in multiple sclerosis practice within Europe - Is it time for a new treatment guideline? |
title_full |
Variations in multiple sclerosis practice within Europe - Is it time for a new treatment guideline? |
title_fullStr |
Variations in multiple sclerosis practice within Europe - Is it time for a new treatment guideline? |
title_full_unstemmed |
Variations in multiple sclerosis practice within Europe - Is it time for a new treatment guideline? |
title_sort |
Variations in multiple sclerosis practice within Europe - Is it time for a new treatment guideline? |
author |
Marziniak, M |
author_facet |
Marziniak, M Ghorab, K Kozubski, W Pfleger, C Sousa, L Vernon, K Zaffaroni, M Meuth, SG |
author_role |
author |
author2 |
Ghorab, K Kozubski, W Pfleger, C Sousa, L Vernon, K Zaffaroni, M Meuth, SG |
author2_role |
author author author author author author author |
dc.contributor.none.fl_str_mv |
RIHUC |
dc.contributor.author.fl_str_mv |
Marziniak, M Ghorab, K Kozubski, W Pfleger, C Sousa, L Vernon, K Zaffaroni, M Meuth, SG |
dc.subject.por.fl_str_mv |
Europa Esclerose Múltipla Disparidades em Assistência à Saúde Padrões de Prática Médica |
topic |
Europa Esclerose Múltipla Disparidades em Assistência à Saúde Padrões de Prática Médica |
description |
In the past 5 years, the combination of developments in diagnostic strategy and approval of new disease-modifying therapies has provided an opportunity to achieve dramatic improvements in patient outcomes in multiple sclerosis (MS). However, across Europe there are several factors that may prevent patients from receiving the best therapy at the appropriate time, and there is variation among countries in terms of which of these factors are most relevant. Here, we review current MS clinical practices in a number of countries in the European Union to identify differences regarding initiation of treatment in patients with clinically isolated syndrome or relapsing-remitting MS, and differences in the timing of treatment switch or escalation. While recognizing that policy is not static in any country, we believe that patients' interests would be better served if a European treatment guideline was developed. Such a guideline could both inform and be informed by national policies, facilitating the dissemination of best clinical practice internationally. |
publishDate |
2016 |
dc.date.none.fl_str_mv |
2016-07 2016-07-01T00:00:00Z 2020-03-21T19:24:05Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/10400.4/2276 |
url |
http://hdl.handle.net/10400.4/2276 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
Mult Scler Relat Disord. 2016 Jul;8:35-44. 10.1016/j.msard.2016.04.004 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.source.none.fl_str_mv |
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1799131709572120576 |